Nivolumab plus ipilimumab (N plus I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

JOURNAL OF CLINICAL ONCOLOGY(2023)

引用 0|浏览17
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要